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Abstract
Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by anti-platelet autoantibody-mediated platelet
destruction. Antigen-presenting cell (APC) dysfunction is considered to play crucial roles in ITP. However, how APC affects
autoreactive B cells in ITP is still unknown. Using a mouse model of immune thrombocytopenia, we demonstrated an
increase in levels of TLR7 in splenic mononuclear cells (SMCs). Using both TLR7 agonist and TLR7 silencing lentivirus, we
found stimulation of TLR7 decreased platelet counts and increased levels of platelet-associated IgG (PAIgG) in ITP mice,
which correlates TLR7 with platelet destruction by autoantibodies. Levels of serum BAFF increased significantly in ITP mice
and stimulation of TLR7 promoted secretion of BAFF. Among the three BAFF receptors, only BAFF receptor (BAFF-R)
increased in ITP mice. However, activation of TLR7 showed no effect on the expression of BAFF receptors. These findings
indicate that upregulation of TLR7 may augment BAFF secretion by APC and through ligation of BAFF-R promote
autoreactive B cell survival and thus anti-platelet autoantibody production. The pathway of TLR7/BAFF/BAFF-R provides us
with an explanation of how activation of APC affects autoantibody production by B cells in ITP and thus might provide a
reasonable therapeutic strategy for ITP.
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Introduction
Immune thrombocytopenia (ITP) is an autoimmune disease
manifested by immune-mediated platelet destruction and sup-
pression of platelet production. Although several abnormalities
involving the cellular mechanisms of immune modulation have
been identified, development of autoantibodies against platelet
glycoproteins remains central in the pathogenesis of ITP [1].
Increasing evidence suggests an important role of deviant APC in
the pathophysiology of autoimmune diseases [2]. Targeting APC
shows promising therapeutic effects in an animal model of
rheumatoid arthritis (RA) [3]. In ITP patients, changes in
number and function of APC have also been indicated [4].
Activation of APC is found to play a critical role in the
pathogenic anti-platelet autoantibody response [4,5]. However,
how activation of APC affects autoantibody producing B cells is
not well elucidated.
Toll-like receptors (TLRs) are type I transmembrane pattern-
recognition receptors (PPRs) that have long been known to
recognize highly conserved, pathogen-associated molecular pat-
terns (PAMPs) [6]. TLRs are expressed on many cell types,
especially APC [7]. They are key mediators of innate immunity
and also regulate activation of adaptive immune system. Evidence
suggests a role for TLRs in immune and inflammatory diseases
and increasingly in autoimmunity [8]. Intracellularly localized
TLR7 participates in APC activation and autoantibody produc-
tion showing obvious importance in autoimmune diseases [9]. In
2006, using DNA microarrays, Sood et al. [10] found elevated
levels of TLR7 in ITP patients. Increased levels of TLR7 in ITP
were also indicated in our previous study using microarray analysis
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e22708(data not published). Nevertheless, the role of TLR7 upregulation
in APC in the pathophysiology of ITP is still unclear.
B cell activating factor (BAFF) is a member of the TNF
superfamily and plays a major role in B cell survival [11]. BAFF
has emerged as a crucial factor that modulates B cell tolerance and
homeostasis. Elevated serum BAFF levels are involved in the
pathogenesis of B cell-mediated autoimmune diseases such as
systemic lupus erythematosus (SLE) [12], multiple sclerosis (MS)
[13], systemic sclerosis (SS) [14] and RA [15]. BAFF binds to three
receptors expressed on B cells: B cell maturation antigen (BCMA),
transmembrane activator and calcium-modulating cyclophilin
ligand interactor (TACI) and BAFF receptor (BAFF-R). Several
lines of evidence indicate interaction between TLRs and BAFF or
its receptors but few regarding the role of TLR7 [16,17].
In the present study, we have explored the hypothesis that
pathway of TLR7/BAFF/BAFF receptors accounts for APC
affecting autoreactive B cells. The expression of TLR7, BAFF and
BAFF receptors was detected in ITP using a thrombocytopenic
mouse model. Then effects of TLR7 on platelet counts and levels
of BAFF and BAFF-R in ITP mice were evaluated in vivo using
TLR7 agonist and TLR7 silencing lentivirus. Our results correlate
TLR7 with disease activity and indicate a role of TLR7/BAFF/
BAFF-R pathway in the pathogenesis of ITP.
Results
Elevated levels of TLR7 in ITP mice
An ITP mouse model was developed according to Musaji [18].
The change of platelet counts was expressed as relative platelet
count, i.e. the ratio of the platelet counts after immunization to the
platelet counts before immunization. Fig. 1A showed that the
decrease of relative platelet count was gradual and reached a
maximum 3 weeks after the first rat platelet administration
(0.4960.15, P=0.000). The experimental mice 3 weeks after the
first immunization were referred to as ‘ITP mice’ in our later
study.
To investigate whether TLR7 is activated in APC, SMCs were
isolated from ITP mice and controls to determine the levels of
TLR7. The relative mRNA expression of TLR7 was increased
3.14-fold (P=0.003) in ITP mice compared to controls (Fig. 1B).
The protein levels of TLR7 were also significantly increased in
ITP mice compared with controls revealed by western blot
(P=0.033, Fig. 1C). Our data indicate that increased levels of
TLR7 are involved in ITP mice.
Effects of TLR7 on platelet counts
In order to explore the effects of TLR7 on ITP mice, TLR7
agonist (imiquimod) and TLR7 silencing lentivirus were used. The
silencing efficiency of lentivirus was validated by transducing
RAW264.7 cells in vitro. In our hands, more than 90% of
RAW264.7 cells were transduced 3 days after transduction
indicated by expression of GFP (Fig. S1A). Then RAW264.7 cells
were harvested to determine the levels of TLR7 by real-time PCR
and western blot. The relative TLR7 mRNA levels in RAW264.7
cells transduced with TLR7 silencing lentivirus was significantly
decreased, only 3.8260.62% relative to controls (P=0.000) (Fig.
S1B). Results of western blot showed that TLR7 silencing
lentivirus can efficiently knockdown protein levels of TLR7 in
RAW264.7 cells (P=0.048, Fig. S1C), thus indicating that TLR7
silencing lentivirus can efficiently knockdown expression of TLR7
in vitro.
TLR7 silencing lentivirus was then used in vivo. The transduc-
tion efficiency of lentivirus in vivo was validated by GFP expression
in spleen frozen sections (Fig. 2A). Four weeks after the first
immunization, SMCs were isolated to determine the mRNA and
protein levels of TLR7. Results of real-time PCR and western blot
showed that TLR7 silencing lentivirus efficiently decreased the
levels of TLR7 in ITP mice both in mRNA and protein levels
(Fig. 2B and C), proving that TLR7 silencing lentivirus works
efficiently in vivo.
The effects of TLR7 on platelet counts were then determined.
TLR7 silencing lentivirus injection significantly increased the
relative platelet counts (1.1160.12 vs 0.8460.09, P=0.025)
whereas imiquimod injection significantly decreased the relative
platelet counts in ITP mice (0.5960.05 vs 0.8460.09, P=0.034).
However, no obvious changes were observed in different groups of
controls (Fig. 3). These findings indicate that activation of TLR7
may negatively regulate platelet counts of ITP mice and thus is
correlated to disease activity.
Effects of TLR7 on PAIgG levels
As development of autoantibodies against platelets remains
central in the pathogenesis of ITP, it is important to detect the
effects of TLR7 on anti-platelet antibodies. Flow cytometry was
Figure 1. The platelet counts and levels of TLR7 in ITP mice and controls. (A) Changes in relative platelet counts of controls (n=8) and
experimental mice (n=10). With rat platelet injection, experimental mice developed progressively thrombocytopenia. The relative platelet countsi n
experimental mice reached the minimum 3 weeks after the first immunization (0.4960.15 vs 1, P=0.000). There was no significant change in controls.
SMCs were isolated from ITP mice (n=10) and controls (n=8) for RNA and protein extraction. (B) Results of real-time PCR analysis showed that the
ratio of TLR7 mRNA in ITP mice compared to that of controls was 3.14 (P=0.003). (C) Increased levels of TLR7 protein in ITP mice were revealed by
western blot. The graph showed the densitometric quantitation of TLR7 to the housekeeping gene GAPDH. Bars represent SD, * represents P,0.05,
** represents P,0.01.
doi:10.1371/journal.pone.0022708.g001
TLR7/BAFF/BAFF Receptor Pathway in ITP
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fluorescence intensity (MFI) was used to evaluate PAIgG levels.
Four weeks after the first immunization, PAIgG levels were
significantly increased in ITP mice compared to controls
(27.4463.68 vs 3.0060.43, P=0.002). Imiquimod injection
significantly increased PAIgG levels (56.63613.20, P,0.001)
whereas TLR7 silencing lentivirus significantly decreased PAIgG
levels (9.9962.78, P=0.026) in ITP mice. No obvious difference
was observed in PAIgG levels among the four groups of controls
(Fig. 4). Together, our results indicated that PAIgG levels were
significantly increased in ITP mice and were promoted by
TLR7.
Effects of TLR7 on BAFF in vitro and in vivo
To elucidate how stimulation of TLR7 in APC affects anti-
platelet antibody producing B cells, we detected the effects of
TLR7 on BAFF levels both in vitro and in vivo. SMCs isolated from
ITP mice and controls were cultured in vitro and the levels of BAFF
in supernatant were detected by ELISA. Compared with controls,
levels of BAFF in supernatant of SMCs were significantly
increased in ITP mice (ITP mice: 766.09643.03 pg/ml, controls:
519.19643.95 pg/ml, P=0.004). Imiquimod significantly in-
creased the levels of BAFF in SMCs supernatant in ITP mice
(1145.176123.70 pg/ml vs 766.09643.03 pg/ml, P,0.001) but
not in controls. TLR7 silencing lentivirus did not cause a
Figure 2. Analysis of TLR7 silencing lentivirus in vivo. The transduction efficiency of lentivirus in vivo was validated by GFP expression in spleen
frozen sections from normal CBA mice (left) and ITP mice transduced with lentivirus (right), respectively. Scale bar, 100 mm. SMCs were isolated from
ITP mice of group I (regarded as ITP mice, n=10) group II (regarded as empty-lenti, n=8) and group III (regarded as TLR7-RNAi mice, n=8). Then
SMCs were used to analyze the mRNA levels and protein levels of TLR7 by real-time PCR (B) and western blot (C), respectively. Bars represent SD,
* represents P,0.05.
doi:10.1371/journal.pone.0022708.g002
Figure 3. Effects of TLR7 on platelet counts. Empty lentiviral
vector, TLR7 silencing lentivirus and imiquimod were used in both ITP
mice and controls. The relative platelet counts of ITP mice were
significantly increased in group III (n=8) whereas decreased in group IV
(n=8) compared with group I (n=10). No obvious changes were
observed in the four groups of controls. Bars represent SD, * represents
P,0.05, ** represents P,0.01.
doi:10.1371/journal.pone.0022708.g003
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controls (Fig. 5A).
Effects of TLR7 on levels of BAFF were determined in vivo.
Before immunization, the levels of serum BAFF in experimental
mice and controls were 7015.276454.33 pg/ml and 7043.456
435.89 pg/ml, respectively. There was no significant difference
between the two groups (P=1). Three weeks after the first
immunization, the levels of serum BAFF in ITP mice were
significantly elevated (12448.346695.23 pg/ml vs 7015.276
454.33 pg/ml, P=0.000) compared to the levels before immuni-
zation. A significant difference was also found between ITP mice
(12448.346695.23 pg/ml) and controls (7920.06375.15 pg/ml)
(P=0.000). No significant difference was found in controls before
and 3 weeks after saline injection (P=0.224) (Fig. 5B).
Four weeks after the first immunization, the levels of serum
BAFF in the four groups of ITP mice and controls were detected.
At this time, the levels of serum BAFF in ITP mice were
significantly increased compared to controls (ITP mice:
8481.666211.54 pg/ml, control mice: 7463.676198.55 pg/ml,
P=0.006). Imiquimod significantly increased the levels of serum
BAFF in ITP mice (10578.436417.54 pg/ml, P=0.001) whereas
TLR7 silencing lentivirus decreased the levels of serum BAFF in
ITP mice (7258.366359.17 pg/ml, P=0.011). No obvious
difference was observed in the four groups of controls (Fig. 5C).
Our results indicate that levels of serum BAFF is elevated in ITP
mice and stimulation of TLR7 promotes secretion of BAFF.
Effects of TLR7 on BAFF receptors
To investigate through which BAFF receptor elevated serum
BAFF affects B cells, the levels of the three BAFF receptors on B
cells in peripheral blood of ITP mice and controls were
determined. Results of flow cytometry showed that among the
three receptors, only BAFF-R increased significantly in ITP mice
when compared to controls (P=0.006, Fig. 6). No significant
difference in BCMA and TACI levels were detected. The median
fluorescence intensity (MFI) of BCMA and TACI in ITP mice was
8.4561.24 and 9.5560.97, respectively. The MFI of BCMA and
TACI in controls was 8.0760.99 and 9.1461.12, respectively
(data not shown). Therefore, elevated BAFF promoting B cell
survival through BAFF-R and suggests that the pathway of TLR7/
BAFF/BAFF-R plays a role in ITP.
As previous studies showed that TLR7 might influence the
expression of BAFF receptors directly [17], effects of TLR7 on
BAFF-R were then determined. Results of flow cytometry showed
no significant difference after stimulation or inhibition of TLR7 in
either controls or ITP mice (Fig. 7). These findings showed that no
direct interaction was found between TLR7 and BAFF-R in ITP
mice. Altogether, our results indicate that stimulation of TLR7 in
APC enhances secretion of BAFF by APC and thus through
ligation of BAFF-R promotes survival of autoreactive B cells and
contributes to autoantibody-mediated platelet destruction in ITP
mice.
Discussion
In this study, a thrombocytopenic mouse model described by
Musaji [18] was used to explore the mechanism of APC affecting
autoreactive B cells. Elevated levels of PAIgG detected in ITP
mice indicate that the drop in platelet counts was due to the anti-
platelet autoantibody-mediated autoimmune response [18]. Addi-
tionally, presence of autoantibodies makes this thrombocytopenic
mouse model suitable for our study on mechanism between APC
activation and B cell autoantibody production. To construct this
thrombocytopenia model, rat platelets were injected into CAB
mice. Rat platelets injection may promote an anti-platelet response
and also additional immune responses. Saline injection in control
mice may not be a good control. However, results of Musaji and
ours showed that anti-platelet autoantibody production [18] and
increased TLR7 and BAFF levels (data supplied on request) are
specific to CBA mice but not in BALB/c mice. This indicates that
the changes observed in our study are mainly due to the anti-
platelet response.
TLR7 was found to be significantly increased in ITP mice.
Elevated levels of TLR7 have also been detected in autoimmune
diseases mediated by autoreactive B-cell clones such as SLE [19]
and even in ITP [10]. Previous studies show that, in SLE, TLR7 is
necessary and sufficient for antibody production. Inhibition of
TLR7 reduces anti-RNA autoantibody production, glomerular
IgG levels and glomerular macrophage infiltration and thus
attenuates glomerulonephritis in lupus mice and represents a
potential therapeutic target in lupus [9,20]. Effects of TLR7 on the
pathology of ITP were determined in our study. In ITP mice,
activation of TLR7 negatively-regulates platelet counts and
increases PAIgG levels. Our results indicate that TLR7 is
correlated with disease activity in ITP and contributes to
autoantibody-mediated platelet destruction. But the potential
source of TLR7 ligand in ITP is still unknown. A pathogen as a
source of ssRNA or human mRNA in an immune complex may
participate in TLR7 stimulation. Additionally, how stimulation of
TLR7 in APC affects production of anti-platelet antibodies by B
cells is not well elucidated in ITP.
Previous studies show that activation of TLRs might influence
expression or secretion of BAFF. Stimulation of TLR4 augmented
BAFF expression in spleen cells in vitro by inducing reactive oxygen
species and increased the total number of B cells in the spleen in
Figure 4. Effects of TLR7 on PAIgG levels. Platelets were collected
from group I, group II (empty lentiviral vector injection), group III (TLR7
silencing lentivirus injection) and group IV (imiquimod injection) of ITP
mice and controls. (A) Flow cytometry was performed to detect PAIgG
levels on the surface of mice platelets of controls (left) and ITP mice
(right). The MFI of PAIgG for different groups was demonstrated as
histogram in (B). PAIgG levels were significantly increased in ITP mice
compared with controls. Stimulation of TLR7 significantly increased
PAIgG levels in ITP mice whereas inhibition of TLR7 significantly
decreased PAIgG levels in ITP mice. No obvious changes were observed
in the four groups of controls. Bars represent SD, * represents P,0.05,
** represents P,0.01.
doi:10.1371/journal.pone.0022708.g004
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expression in human bronchial epithelial cells via an autocrine
pathway involving IFN-b. Thus through local accumulation,
activation and Ig synthesis by B cells in the airway, TLR3 plays an
important role in airway immune responses [16]. However,
contrary results were reported elsewhere. Elevated levels of BAFF
were detected in RA patients. But none of the ligands of TLR2,
TLR4 and TLR9 induced the de novo synthesis and release of
BAFF by synoviocytes. In addition, IFN-c-induced BAFF synthesis
was inhibited by stimulation of TLR2, 4, 9 [22]. In our study,
significantly elevated levels of serum BAFF were detected in ITP
mice. This result suggests that BAFF participates in the
pathogenesis of ITP. This is in accordance with the results of
previous studies concerning other autoimmune disorders [12–14].
In conclusion, our results showed that levels of serum BAFF was
positively regulated by TLR7 in ITP mice indicating that elevated
TLR7 augmented secretion of BAFF by APC in ITP.
BAFF, a crucial homeostatic cytokine for B cells, exerts its role
through binding to its receptors: BCMA, TACI and BAFF-R. A
proliferation inducing ligand (APRIL), a cytokine homologous to
BAFF, can bind to BCMA and TACI but not BAFF-R which
makes BAFF-R a specific receptor for BAFF [23]. BAFF-R,
expressed on a wide range of B cell subsets, is the predominant
receptor that mediates BAFF-dependent B cell signaling and plays
critical roles in controlling peripheral B cell survival [3]. BAFF-R
was often found increased in autoantibody related diseases [24].
However, some studies showed that expression of BAFF-R did not
change or even decrease in autoimmune diseases including SLE,
SS, MS and RA [15,25–27]. Results of Zhou et al. showed that
mRNA expression of BAFF-R did not change in peripheral blood
Figure 5. Effects of TLR7 on BAFF levels in vitro and in vivo. (A) Effects of TLR7 on BAFF levels in vitro were evaluated by SMCs culture. SMCs
obtained from controls and ITP mice were divided into four groups and treated with or without empty lentiviral vector, TLR7 silencing lentivirus or
imiquimod, respectively. The supernatant was collected and the levels of BAFF were determined by ELISA. (B) Serum samples were obtained from
the experimental mice (n=10) and controls (n=8) before immunization and 3 weeks after the first immunization. A significant increase of serum
BAFF was detected in ITP mice (At the time of 3 weeks after the first immunization, the experimental mice were regarded as ‘ITP mice’.) The
difference between ITP mice and controls was also significant. (C) Effects of TLR7 on BAFF in vivo were determined using mice serum. Both controls
and ITP mice were divided into four groups and treated with or without empty lentiviral vector, TLR7 silencing lentivirus or imiquimod,
respectively. The serum from each group was obtained and the levels of BAFF were determined by ELISA. Bars represent SD, * represents P,0.05,
** represents P,0.01.
doi:10.1371/journal.pone.0022708.g005
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Unfortunately, the protein levels of BAFF-R were not detected in
their research. Here, our study indicated a significant increase of
BAFF-R while no changes in BCMA and TACI on peripheral B
cells in ITP mice. Our results suggested that excess BAFF promoted
autoreactive B cell survival by binding to BAFF-R in ITP.
ExceptfortheeffectsonexpressionofBAFF,stimulationofTLRs
may also influence expression of BAFF receptors directly. TLRs,
together with BAFF receptors were shown to regulate the function
and homeostasis of B cells. Activation of TLR9 strongly elevated
TACI levels on B cells in a MyD88-dependent pathway whereas
TLR4 ligand might increase both TACI and BAFF-R levels in
MyD88-dependent and independent pathways [17]. In lupus-like
mice, activation of TLR7/9 led to a strong upregulation of TACI
[29]. In our study, either activation of TLR7 or inhibition of TLR7
made no significant difference in the expression of BAFF-R. This
indicates that TLR7 does not interact with BAFF-R directly in ITP
but exerts its role through interaction with BAFF.
Additionally, B cells also express TLR7. Stimulation of TLR7
may augment BAFF secretion by B cells and thus through ligation
of BAFF receptors promotes autoreactive B cell survival. To
separate this direct effect of B cells from the indirect effect via APC
described in our work, specific stimulation or silencing of TLR7 in
APC is needed.
Insummary,levelsofTLR7areelevatedinITPmice.Stimulation
of TLR7 is related to disease activity by promoting platelet
destruction through anti-platelet antibodies in ITP mice. The levels
of serum BAFF are increased in ITP mice and stimulation of TLR7
promotes secretion of BAFF. Among the three BAFF receptors, only
BAFF-R is elevated in ITP mice. No direct interaction between
TLR7 and BAFF-R is detected. These results indicate a role of
TLR7/BAFF/BAFF-R in the pathogenesis of ITP. The pathway of
TLR7/BAFF/BAFF-R provides us with an appropriate explanation
of how activation of APC affects autoreactive B cells and
autoantibody production in ITP and thus regulating this pathway
might provide a reasonable therapeutic strategy for ITP.
Materials and Methods
Lentiviral silencing vector
Lentiviral silencing vector targeting mouse TLR7 (NM_133211)
was constructed and packaged by Genechem. The target sequence
of the TLR7 silencing vector was 59-GATCTGCCATCCAGCT-
TACAT-39 [30]. RAW264.7 cells [31] were transduced with
lentivirus at a multiplicity of infection (MOI) of 20 in serum free
medium containing 10 mg/ml polybrene in 6-well plates. After
8 h, DMEM medium containing 10% FBS was added to the cells.
Three days later, the transduction efficiency was evaluated by
expression of GFP (Both of the lentiviral vectors contain a GFP
expression cassette) and the RAW264.7 cells were collected for
RNA and protein extraction.
Mouse model
Female CBA mice about 7 weeks old were purchased from
Shanghai Slac Laboratory Animal Limited Company and the study
was approved by the Ethics Committee of Shandong University
School of Medicine (No. 005 in 2008 for Animal Ethics Approval).
This model was first described by Musaji [18]. Briefly, blood of
Wistar rats was collected from jugular vein. Platelet-rich superna-
tant was prepared by successive centrifugations. Platelets were
pelleted from this supernatant and washed as appropriate. Then rat
platelets were used to immunize experimental mice. Rat platelets
10
8 in 0.5 ml saline were first administered intraperitoneally,
followed by 0.5610
8 platelets weekly. Controls were injected with
saline alone. Blood was collected from the retro-orbital plexus of
ether-anesthetized CBA mice and platelets were counted by
Hemavet 950 Animal Haematology Analyzer (Drew Scientific).
Figure 6. Flow cytometry analysis for the expression of BAFF-R in ITP mice and controls. Peripheral blood samples were obtained from
ITP mice (n=10) and controls (n=8). Two-color staining was carried out on blood samples. (A) A representative experiment shown here indicated a
significant increase of BAFF-R in ITP mice (black) compared with controls (blank). (B) The MFI of BAFF-R is presented as mean 6 SD in histogram. Bars
represent SD, ** represents P,0.01.
doi:10.1371/journal.pone.0022708.g006
Figure 7. Effects of TLR7 on BAFF-R levels. Both controls and ITP
mice were divided into four groups and treated with or without empty
lentiviral vector, TLR7 silencing lentivirus or imiquimod, respectively.
Blood samples were collected from each group and the levels of BAFF-R
on B cells were determined by flow cytometry. Stimulation or inhibition
of TLR7 made no significant difference in the levels of BAFF-R in both
control mice (left) and ITP mice (right).
doi:10.1371/journal.pone.0022708.g007
TLR7/BAFF/BAFF Receptor Pathway in ITP
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minimum platelet counts were regarded as ‘ITP mice’. The ITP
mice and controls were divided into four groups, respectively:
group I received rat platelets (n=10) or saline (n=8) injection as
before, group II received injection of rat platelets (n=8) or saline
(n=8) once plus tail intravenous injection of 10
7 transduction unit
(TU) empty lentiviral vector, group III received rat platelets (n=8)
or saline (n=8) injection once plus tail intravenous injection of 10
7
transduction unit (TU) lentiviral silencing vector of TLR7 and
group IV received rat platelets (n=8) or saline (n=8) injection
once plus 25 mg imiquimod (TLR7 agonist) (InvivoGen) every
other day [32]. Effects of TLR7 were detected one week later (i.e.
four weeks after the first immunization).
Splenic mononuclear cells (SMCs)
SMCs were isolated from spleens of mice using 1.092 g/ml
Ficoll-Hypaque (TBD) gradient centrifugation (2 000 rpm for
20 min, 20uC). The isolated SMCs were washed twice with PBS
for culture, RNA and protein extraction. For culture, the isolated
SMCs were diluted to 10
6/ml and seeded into RPMI 1640
medium supplemented with 10% FBS and 10 ng/ml IL-2. The
SMCs in culture were divided into four groups: group I (without
treatment), group II (transduced with empty lentiviral vector),
group III (transduced with TLR7 silencing lentivirus) and group
IV (imiquimod 10 mg/ml). Then on day 3 the supernatant of
SMCs was collected for ELISA analysis.
Quantitative real-time PCR analysis
Total RNA was isolated from cells with TRIzol reagent
(Invitrogen). The amount of RNA was determined using ultraviolet
spectrophotometer DU800 (Beckman) and normalized to 1 mg/ml.
Total RNA was converted into cDNA using the PrimeScript
TM RT
reagent kit (Takara). Real-time PCR was performed for TLR7 and
GAPDH on Lightcycler 2.0 (Roche) using SYBR Premix Ex Taq
(Takara). The sequences of the amplification primers for TLR7 and
GAPDH are as follows: TLR7 forward, 59-CCTAGGA-
CATGCCTTGGTACCTG-39, TLR7 reverse, 59-CCCAC-
CAATCTGAGCCATGA-39; GAPDH forward, 59-
TGTGTCCGTCGTGGATCTGA-39, GAPDH reverse, 59-
TTGCTGTTGAAGTCGCAGGAG-39. LightCycler Software
4.0 (Roche) was used to determine Ct value. All PCR products
were visualized by 2% agarose gel electrophoresis stained by
ethidium bromide. The mRNA expression of TLR7 was normal-
ized to GAPDH relative to control using 2
2DDCt method [33].
Western blot
Cells were lysed in RIPA Lysing Buffer (Beyotime). The total
protein was extracted after homogenization and centrifugation.
The protein concentration was determined using BCA Protein
Assay Kit (Pierce). GAPDH was used to normalize the amount of
protein in all western blot experiments. Proteins were loaded onto
SDS-PAGE and transferred to a nitrocellulose membrane. The
membrane was probed with antibodies to TLR7 (Abcam) and
GAPDH (Jingmei). The secondary antibody used was HRP anti-
rabbit antibody (Jingmei). Protein bands were visualized with ECL
system (Pierce).
ELISA
Peripheral blood samples from CBA mice clotted for 2 h at
room temperature and were centrifuged to obtain serum.
Supernatant from SMCs was collected by centrifugation. Then
levels of BAFF in serum and supernatant were measured by
Quantikine Mouse BAFF/BLyS/TNFSF13B Immunoassay
(R&D) in 96-well microtiter according to manufacture’s instruc-
tion. The lower detection limit of the assay was 4.3 pg/ml.
Flow cytometry
For determination of BAFF receptors, peripheral blood samples
of CBA mice 100 ml were incubated with 2.5 ml PerCP-Cy5.5 anti-
mouse B220 and 0.625 ml PE anti-mouse TACI or 5 ml Alexa
Flour 647 anti-mouse BAFF-R (eBioscience) or 20 ml monoclonal
anti-mouse BCMA-Fluorescein (R&D) for 30 min. B220 was used
to label B cells and was co-stained with the three BAFF receptors,
respectively. Then 2 ml 16FCM Lysing Solution (MultiSciences
Biotech) was added and the samples were incubated in the dark for
10 min. For detection of platelet-associated IgG (PAIgG), 2610
7
mice platelets were incubated with 1 ml FITC anti-mouse IgG
(H+L) for 30 min.
After centrifuge to remove supernatant, the cell and platelet
pellets were washed with PBS twice. Finally, 300 ml PBS were
added to resuspend the cell and platelet pellets and the samples
were determined by flow cytometer (BD Biosciences). The data
were analyzed using FCS Express V3.
Statistical analysis
Data were expressed as mean 6 SD. Statistical significance was
determined by one-way analysis of variance (ANOVA) using the
Statistical Package for the Social Sciences (SPSS) version 13.0. P
value less than 0.05 was considered statistically significant.
Supporting Information
Figure S1 Knockdown of TLR7 by silencing lentivirus in vitro.
Lentivirus expressing shRNA targeting mouse TLR7 and empty
lentiviral vector were transduced into RAW264.7 cells and
regarded as TLR7-RNAi and empty-lenti, respectively. (A) Three
days after transduction, more than 90% of RAW264.7 cells were
transduced as indicated by expression of GFP. Scale bar, 200 mm.
Then RAW264.7 cells were harvested for RNA and protein
extraction. (B) The mRNA levels of TLR7 were detected by real-
time PCR. The data were presented as percentage in gene
expression normalized to GAPDH relative to controls. (C) The
protein levels of TLR7 were determined by western blot. The
graph showed the densitometric quantitation of TLR7 to the
housekeeping gene GAPDH. Expression of TLR7 in both mRNA
and protein levels was efficiently knocked down by TLR7 silencing
lentivirus in RAW264.7 cells. Bars represent SD, * represents
P,0.05, ** represents P,0.01.
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